Background The use tumor-derived cell-free DNA extracted from body fluids is being
evaluated for genetic testing in lung cancer. The aim of this study was to explore the …

Purpose: Resistance to tyrosine kinase inhibitors (TKIs) in lung cancer often occurs, so
mutation testing from liquid biopsy is the method of choice as a minimally invasive approach …

Background: Mutation of epidermal growth factor receptor (EGFR) is a prediction marker of
the response to tyrosine kinase inhibitor (TKI) drugs in non-small cell lung cancer (NSCLC) …

Background and objective The lack of pathological quality control standard in detecting
epidermal growth factor receptor (EGFR) gene mutation in malignant pleural effusion leads …

Previous studies focus on developing high sensitive PCR-related technologies to detect
EGFR gene mutation in malignant pleural effusion (MPE) of non-small cell lung cancer …

Peptide nucleic acid (PNA)-mediated real-time PCR clamping has higher sensitivity than
conventional direct sequencing for detecting mutations. Pleural effusion and serum may …

Malignant pleural effusion (MPE) is a useful specimen allowing for the evaluation of EGFR
status in nonsmall cell lung cancer (NSCLC). However, direct sequencing of genomic DNA …

Aims To evaluate the suitability of malignant pleural effusion (MPE) and plasma as surrogate
samples for epidermal growth factor receptor (EGFR) mutation detection, and compare three …

Purpose: The therapeutic choice for patients with lung adenocarcinoma depends on the
presence of EGF receptor (EGFR) mutations. In many cases, only cytologic samples are …

Objectives The utility of malignant pleural effusion (MPE) as a source for determining EGFR
mutations to guide EGFR TKI therapy in advanced adenocarcinoma of the lung remains …